Heinrich Rueeger

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease

Ulf Neumann, Mike Ufer, Laura H. Jacobson et al. · EMBO Molecular Medicine · 2018 · 172 citations · Full text

Medicine, Neuroscience, Pharmacology +12

Targeting Presenilin-type Aspartic Protease Signal Peptide Peptidase with γ-Secretase Inhibitors

Andreas Weihofen, Marius K. Lemberg, Elena Friedmann et al. · Journal of Biological Chemistry · 2003 · 125 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

Ulf Neumann, Heinrich Rueeger, Rainer Machauer et al. · Molecular Neurodegeneration · 2015 · 110 citations · Full text

Medicine, Neurology, Pharmacology +17

Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides

Heinrich Rueeger, Rainer Lueoend, Olivier Rogel et al. · Journal of Medicinal Chemistry · 2012 · 99 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition

Dorothée Abramowski, Karl‐Heinz Wiederhold, Ulrich Furrer et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 90 citations

Life Sciences, Biochemistry, Neuroscience +17